Domain: Digital Health, Sleep Medicine, B2B2C
Stage: Ideation & Initial Validation
When: April 2026 – June 2026
Team Skill Set: Marketing entrepreneur with a consumer and mobility background, previously CEO of a mobility-focused incubator; domain-expert co-founder, a practicing sleep physician heading a hospital sleep department; Tech Lead with a fintech and payments background
Thesis
The idea started with a conversation between friends. A business entrepreneur and a physician who runs a sleep department at a hospital, discussing how they can re-think the model of today’s sleep labs. The entrepreneur came with zero background in this field, and as he dug into it with his physician friend over the following weeks, he discovered a genuinely fascinating, under-examined corner of healthcare.
A few facts framed the opportunity. First, people spend roughly a third of their lives asleep, yet the field has seen almost no real innovation. Second, as a use-case, In Israel for example, a country of millions, there are only about twenty practicing sleep physicians. Third, The most common treatment today for sleep apnea is a machine invented decades ago, largely unchanged since. And most strikingly: an estimated 80% of people who likely have a diagnosable sleep problem never identify it as one – they just live with being tired, irritable, or unwell, without connecting it to how they sleep.
The idea that formed: instead of another sleep clinic, build a pre-diagnostic data layer that could triage patients before they ever needed an in-person, overnight sleep study – historically the only real entry point into treatment, and a scarce, slow, uncomfortable one. The layer would combine three inputs: passive data pulled from wearables (rings, watches, fitness trackers) via the Apple Health and Google Health APIs that most people already had sitting on their wrist; a short intake survey; and a facial scan, since physicians said a surprising amount of a sleep-disorder diagnosis is visible in jaw and airway structure alone. Combined, doctors could walk into a first appointment already knowing most of what they needed – and could conduct that appointment remotely, over video, instead of requiring a physical visit.
The thesis extended past diagnosis. Most patients who do see a sleep physician go exactly once and never return, so there’s no way to know if the treatment worked. Connecting a patient’s wearable data into an ongoing feedback loop after diagnosis could close that gap – flagging when a treatment wasn’t working and giving the physician a reason, and a revenue path, to re-engage.
“Eighty percent of people with a real sleep problem don’t even know they have one. That’s the whole opportunity and the whole obstacle in a single number.”
Validation
The physician co-founder’s network did a lot of the early lifting. Within weeks, the team was speaking directly with some of the top sleep specialists internationally – a level of access that would have taken months to build from a cold start.
To understand a viable business model, they also spoke with roughly five Israeli entrepreneurs who had previously built companies in health-tech and adjacent regulated industries. The pattern in every conversation was the same: an immediate warning to stay away from health-tech, paired with an acknowledgment that something keeps founders coming back to it anyway. Regulatory approval processes came up early and often, and it became clear that any real product would eventually need to clear them.
A recurring theme was geography. Most of the category’s activity, funding, and precedent sat in the US, a market the team had no existing relationships in. That pushed them to explore alternatives – Europe, with healthcare systems closer to a public model, and framings like preventive medicine or longevity, given the physician’s data showing strong correlations between poor sleep and heart attack risk, diabetes, obesity, and worse seizure outcomes for epilepsy patients.
One direct test came through a conversation with an investor connected to the insurance industry. The reaction was polite interest – “interesting” – but nothing more. There was no visible spark, no one asking to write a check on the spot. The physician co-founder also attended the largest global sleep medicine conference a few months into the process and came back with a clear signal: a year earlier, almost nobody was building in this space; now, hundreds of startups were chasing the identical idea.
“An investor in insurance told us it was interesting. That was it – no urgency, no one leaning in. I couldn’t help but compare that to the other ideas I’ve brought to people in the past, where the reaction was: “Bring me this, I want in.”
Why it didn’t progress
1. No one could locate a single, willing payer. The team explored US insurers, Israeli public health funds, and European public systems, and never converged on a clear answer to who actually holds the incentive – and the budget – to pay for a pre-diagnosis layer like this.
2. It was a complicated time to build this type of company from Israel. Every health-tech veteran they spoke to advised against building this as an Israeli company at all, describing a real, current bias against Israeli-founded companies in the category – even for grants and programs that used to be more accessible. Combined with an already saturated, relationship-driven US market, that closed off the most obvious path forward.
3. The team lacked category fluency. None of the three co-founders had a health-tech background going in, and the vocabulary, referral logic, and regulatory maze took real time to absorb – described internally as “not speaking the language” of the industry, a gap that felt very different from ventures where a founder’s prior domain experience carries over directly.
4. The competitive landscape changed underneath them. In the space of roughly a year, the market went from nearly empty to crowded with well-capitalized entrants building close variations of the same idea, undercutting the differentiation the team was counting on just as they were shaping a go-to-market plan.
5. Team composition worked against fundability. A sleep physician plus two founders without healthcare pedigree is a real team – but next to increasingly specialized, well-funded competitors, it read as a harder sell to outside investors asking “why this team, why now.”
After about two and a half months, the combination of an unclear business model, discouraging feedback from people who’d tried this before, and a suddenly crowded field was enough for the team to stop.
“Every time we got somewhere, someone who’d already tried this told us to turn back. Eventually you have to ask why so many smart people keep hitting the same wall.”
Insights
1. A huge “undiagnosed” number is a distribution problem wearing a market-size costume. Eighty percent of an addressable population not knowing they have the problem you solve sounds enormous – but it also means the hardest, most expensive part of the business is getting someone’s attention before they’ve ever thought about the issue.
2. In regulated, payer-driven categories, find the payer before you build anything else. The team built out a full data-collection thesis before nailing down who would actually pay for it. In hindsight, mapping insurer and public-system incentives should have been the very first step, not a question tackled two months in.
3. Domain fluency in healthcare isn’t a nice-to-have – it’s the entry fee. Nearly every experienced person they spoke to gave some version of the same warning: this is not a market you can improvise your way through. A tech background that transfers easily in other industries doesn’t automatically transfer here.
4. A category can flip from empty to crowded within a single year. Conference floor conditions changed entirely between one year and the next. Founders entering any suddenly-hot category should treat market saturation as something to re-check continuously, not a box ticked once at the start.
5. Investors read team composition as a signal of execution risk. A strong domain expert paired with generalist operators can build something real – but it doesn’t automatically look fundable to outside capital being asked to bet on a category they don’t understand either.
6. Mission-driven categories are the hardest to walk away from – which is exactly why they require more discipline, not less. The emotional pull of building something that could materially change how people feel every day made this a difficult idea to let go of, even once the data pointed toward stopping.
“There’s a real business here – I still believe that. But it needs a business model nobody’s cracked yet, and probably a team that’s already lived inside this industry. We’ll come back to it. Just not yet.”
